 |
 |
 |
|
Tolerability and persistence of dolutegravir-based regimens: Second interim analysis of the prospective multicenter DOL-ART cohort
|
|
|
Reported by Jules Levin
EACS - 16TH EUROPEAN AIDS CONFERENCE - MILAN, ITALY Oct 23-25
Bohr U1, Bickel M, Hegener P, Hillenbrand H4, Kuhlmann B5, Pauli R6, Mayr C7, Wuensche T8, Luftenegger D9, Sych M10, Westermayer B10, Walli RK9
1Praxiszentrum Kaiserdamm, Berlin; Infektiologikum, Frankfurt; MVZ Dusseldorf; 4Praxis City Ost, Berlin; 5Praxis Georgenstraße, Hannover; 6Isarpraxis, Munich; 7MVZ Finnländische Straße, Berlin; 8Praxis Wuensche, Berlin; 9ViiV Healthcare, Munich; 10GlaxoSmithKline, Munich



|
|
|
 |
 |
|
|